Skip to main content
. Author manuscript; available in PMC: 2018 Feb 28.
Published in final edited form as: Leuk Lymphoma. 2016 Jun 23;58(2):288–297. doi: 10.1080/10428194.2016.1190970

Figure 2.

Figure 2

Figure 2

A. Cumulative Incidence of Relapse based on D56 UCB CD3 Chimerism AML-MDS

B. Cumulative Incidence of Relapse based on D56 UCB CD33 Chimerism AML-MDS

C. Progression Free Survival based on D56 UCB CD3 Chimerism-AML-MDS

D. Progression Free Survival based on D56 UCB CD33 Chimerism-AML-MDS